The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Future Cardiology, published by Future Medicine Ltd, is an esteemed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 1479-6678 and an E-ISSN of 1744-8298, this journal has been serving as a vital platform for researchers and healthcare professionals since its inception in 2006. The journal features rigorously peer-reviewed articles, offering insights into innovative treatments, clinical studies, and cutting-edge research developments. Although it is currently categorized as Q3 in Cardiology and Cardiovascular Medicine and Q4 in Molecular Medicine, its growing impact is evident in its dedicated audience and commitment to fostering dialogue in the cardiovascular community. Future Cardiology provides an invaluable opportunity for scholars to share their findings and enhance knowledge in this critical area of healthcare, a pursuit that is ever more important as cardiovascular diseases continue to be a leading health concern worldwide. Access options are through standard subscriptions, allowing in-depth exploration of articles that push the boundaries of cardiological science.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

Nepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.

Giornale Italiano di Cardiologia is a premier journal in the field of cardiology, published by PENSIERO SCIENTIFICO EDITORE. Established in 1996, this journal serves as an essential platform for sharing the latest research and clinical advancements in cardiovascular medicine, particularly catering to the Italian and international medical communities. Although currently classified in the Q4 quartile for Cardiology and Cardiovascular Medicine (2023), the journal strives to enhance its impact and outreach by embracing rigorous peer-review practices and promoting high-quality submissions. With a commitment to enriching knowledge and fostering dialogue among researchers, clinicians, and students, the journal offers a collection of articles that include original research, reviews, and case studies. While currently not an Open Access publication, readers will benefit from a wealth of research insights that contribute to advancements in cardiac care and treatment strategies. As the Giornale Italiano di Cardiologia continues to evolve, it plays a vital role in bridging research and clinical practice in the cardiovascular domain.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.